Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 윤채옥 | - |
dc.date.accessioned | 2022-07-29T04:12:04Z | - |
dc.date.available | 2022-07-29T04:12:04Z | - |
dc.date.issued | 2020-10 | - |
dc.identifier.citation | MOLECULAR THERAPY, v. 28, NO 10, Page. 2286-2296 | en_US |
dc.identifier.issn | 1525-0016 | - |
dc.identifier.issn | 1525-0024 | - |
dc.identifier.uri | https://www.sciencedirect.com/science/article/pii/S1525001620303543?via%3Dihub | - |
dc.identifier.uri | https://repository.hanyang.ac.kr/handle/20.500.11754/171935 | - |
dc.description.abstract | CRISPR-Cas12a represents a class 2/type V CRISPR RNA-guided endonuclease, holding promise as a precise genome-editing tool in vitro and in vivo. For efficient delivery of the CRISPR-Cas system into cancer, oncolytic adenovirus (oAd) has been recognized as a promising alternative vehicle to conventional cancer therapy, owing to its cancer specificity; however, to our knowledge, it has not been used for genome editing. In this study, we show that CRISPR-Cas12a mediated by oAd disrupts the oncogenic signaling pathway with excellent cancer specificity. The intratumoral delivery of a single oAd co-expressing a Cas12a and a CRISPR RNA (crRNA) targeting the epidermal growth factor receptor (EGFR) gene (oAd/Cas12a/crEGFR) induces efficient and precise editing of the targeted EGFR gene in a cancer-specific manner, without detectable off-target nuclease activity. Importantly, oAd/Cas12a/crEGFR elicits a potent antitumor effect via robust induction of apoptosis and inhibition of tumor cell proliferation, ultimately leading to complete tumor regression in a subset of treated mice. Collectively, in this study we show precise genomic reprogramming via a single oAd vector-mediated CRISPR-Cas system and the feasibility of such system as an alternative cancer therapy. | en_US |
dc.description.sponsorship | This work was supported by grants from the National Research Foundation of Korea (2016M3A9B5942352 to C.-O.Y., 2016R1C1B2015558 to A.-R.Y., and 2019R1C1C1005851 to T.K.); the Korea Drug Development Fund (KDDF) funded by MSIP, MOTIE, and MOHW (KDDF-201611-05, Republic of Korea; to A.-R.Y.); Hanyang University (HY-2011-G201100000001880 to C.-O.Y.); Kyung Hee University (KHU-20182180 to T.K.); and by the Institute for Basic Science (IBS-R021-DJ to J.-S.K.)., South Korea. | en_US |
dc.language.iso | en | en_US |
dc.publisher | CELL PRESS | en_US |
dc.subject | ONCOLYTIC ADENOVIRUS | en_US |
dc.subject | ACQUIRED-RESISTANCE | en_US |
dc.subject | CRISPR-CAS | en_US |
dc.subject | DL1520 ONYX-015 | en_US |
dc.subject | GENE DELIVERY | en_US |
dc.subject | LUNG-CANCER | en_US |
dc.subject | PHASE-II | en_US |
dc.subject | CPF1 | en_US |
dc.subject | MET | en_US |
dc.subject | ANGIOGENESIS | en_US |
dc.title | CRISPR-Cas12a with an oAd Induces Precise and Cancer-Specific Genomic Reprogramming of EGFR and Efficient Tumor Regression | en_US |
dc.type | Article | en_US |
dc.relation.no | 10 | - |
dc.relation.volume | 28 | - |
dc.identifier.doi | 10.1016/j.ymthe.2020.07.003 | - |
dc.relation.page | 2286-2296 | - |
dc.relation.journal | MOLECULAR THERAPY | - |
dc.contributor.googleauthor | Yoon, A-Rum | - |
dc.contributor.googleauthor | Jung, Bo-Kyeong | - |
dc.contributor.googleauthor | Choi, Eunyoung | - |
dc.contributor.googleauthor | Chung, Eugene | - |
dc.contributor.googleauthor | Hong, JinWoo | - |
dc.contributor.googleauthor | Kim, Jin-Soo | - |
dc.contributor.googleauthor | Koo, Taeyoung | - |
dc.contributor.googleauthor | Yun, Chae-Ok | - |
dc.relation.code | 2020054591 | - |
dc.sector.campus | S | - |
dc.sector.daehak | COLLEGE OF ENGINEERING[S] | - |
dc.sector.department | DEPARTMENT OF BIOENGINEERING | - |
dc.identifier.pid | chaeok | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.